Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 8851-8860 Newer>

Pharmaceutical Executive June 1, 2014 Jill Wechsler	What Price Innovation? Payers, drug plans seek clear assessment of drug value to rationalize high drug prices.
Pharmaceutical Executive June 1, 2014 Jill Wechsler	Compassionate Use Requests Complicate Drug Development Pharma, HCPs, and regulators walk tightrope in addressing early-access push while supporting biomedical R&D.
Pharmaceutical Executive June 1, 2014 dos Santos & Leskin	Social Media and the In-House Counsel Social media poses a regulatory and litigation maze that must be carefully navigated by pharmaceutical companies.
Pharmaceutical Executive June 1, 2014 O'Connor et al.	Challenges to the Specialty Business Model New constraints require new solutions. Innovative, value-based pricing models will be critical to securing reimbursement and continued market access of high-price drugs.
Chemistry World June 4, 2014 Phillip Broadwith	Generics giants jostle over pain drug The US Food and Drug Administration has approved the first batch of generic competitors to Pfizer's non-steroidal anti-inflammatory Celebrex (celecoxib).
Chemistry World June 3, 2014 Phillip Broadwith	Drug companies rapped for anticompetitive behavior The Italian health ministry is following up on rulings from the country's competition authorities and demanding billions of euros in damages resulting from anticompetitive behavior.
Chemistry World May 29, 2014 Phillip Broadwith	Boehringer to settle blood thinner drug suits for $650m Boehringer-Ingelheim has committed $650 million to settle around 4000 US court cases relating to its anticoagulant stroke prevention drug Pradaxa (dabigatran).
Chemistry World May 29, 2014 Hepeng Jia	Chinese-made DNA sequencer aims to challenge foreign dominance With an independently developed next-generation DNA sequencer, Chinese scientists are aiming to challenge the dominance of international players in the world's fastest growing genome sequencing market.
Chemistry World May 29, 2014 Derek Lowe	Messy megamergers There is a good deal to be said about drug company mergers in general.
Chemistry World May 28, 2014 Phillip Broadwith	Time called on Pfizer -- AstraZeneca deal Pfizer's pursuit of a pharmaceutical megamerger has concluded with the US giant withdrawing its final offer two hours before the deadline set by the UK's takeover rules.
<Older 8851-8860 Newer> Return to current articles.